GR3033817T3 - Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations - Google Patents

Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations

Info

Publication number
GR3033817T3
GR3033817T3 GR20000401517T GR20000401517T GR3033817T3 GR 3033817 T3 GR3033817 T3 GR 3033817T3 GR 20000401517 T GR20000401517 T GR 20000401517T GR 20000401517 T GR20000401517 T GR 20000401517T GR 3033817 T3 GR3033817 T3 GR 3033817T3
Authority
GR
Greece
Prior art keywords
arachidonic acid
treatment
methods
acid metabolite
unilamellar liposomal
Prior art date
Application number
GR20000401517T
Other languages
English (en)
Inventor
Marc J Ostro
Andrew S Janoff
Sharma R Minchey
Original Assignee
Liposome Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Corp filed Critical Liposome Corp
Publication of GR3033817T3 publication Critical patent/GR3033817T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
GR20000401517T 1993-11-04 2000-06-29 Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations GR3033817T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14789893A 1993-11-04 1993-11-04
US15285293A 1993-11-16 1993-11-16
US18008994A 1994-01-11 1994-01-11
PCT/US1994/012579 WO1995012388A1 (en) 1993-11-04 1994-11-03 Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations

Publications (1)

Publication Number Publication Date
GR3033817T3 true GR3033817T3 (en) 2000-10-31

Family

ID=27386612

Family Applications (2)

Application Number Title Priority Date Filing Date
GR990403099T GR3032006T3 (en) 1993-11-04 1999-11-30 Multilamellar liposomal arachidonic acid metabolite formulations
GR20000401517T GR3033817T3 (en) 1993-11-04 2000-06-29 Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR990403099T GR3032006T3 (en) 1993-11-04 1999-11-30 Multilamellar liposomal arachidonic acid metabolite formulations

Country Status (13)

Country Link
EP (2) EP0726764B1 (el)
JP (2) JPH09511216A (el)
KR (2) KR100355246B1 (el)
AT (2) ATE191141T1 (el)
AU (2) AU687921B2 (el)
CA (2) CA2175896A1 (el)
DE (2) DE69423773T2 (el)
DK (2) DK0726763T3 (el)
ES (2) ES2136271T3 (el)
GR (2) GR3032006T3 (el)
NO (2) NO312810B1 (el)
PT (1) PT726763E (el)
WO (2) WO1995012389A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
ATE233552T1 (de) * 1996-07-22 2003-03-15 Monsanto Co Thiol-sulfonen als metalloproteinaseinhibitoren
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
WO1999025687A1 (en) 1997-11-14 1999-05-27 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
KR20010102000A (ko) 1999-02-08 2001-11-15 윌리암스 로저 에이 술파마토 히드록삼산 메탈로프로테아제 억제제
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
WO2013039851A1 (en) 2011-09-12 2013-03-21 Mallinckrodt Llc Optical agents for imaging and visualization of matrix metalloproteinase enzymes
CN111053743B (zh) * 2018-10-16 2023-07-14 石药集团中奇制药技术（石家庄）有限公司 一种前列地尔脂质体及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
WO1988009170A1 (en) * 1987-05-22 1988-12-01 The Liposome Company, Inc. Prostaglandin-lipid formulations
JPH0395118A (ja) * 1989-09-07 1991-04-19 Green Cross Corp:The プロスタグランジン含有脂肪小体製剤
JPH04356421A (ja) * 1991-03-06 1992-12-10 Green Cross Corp:The プロスタグランジン類含有脂肪小体組成物
ES2128343T3 (es) * 1991-05-07 1999-05-16 Liposome Co Inc Formulaciones de prostaglandina liposomica.
JPH05139977A (ja) * 1991-05-17 1993-06-08 Green Cross Corp:The プロスタグランジン類リポソーム複合体を充填した注射器

Also Published As

Publication number Publication date
AU687921B2 (en) 1998-03-05
DE69423773T2 (de) 2000-07-20
WO1995012389A1 (en) 1995-05-11
WO1995012388A1 (en) 1995-05-11
JPH09504793A (ja) 1997-05-13
KR960705544A (ko) 1996-11-08
KR100355246B1 (ko) 2003-01-06
AU8130894A (en) 1995-05-23
KR960705543A (ko) 1996-11-08
EP0726764A1 (en) 1996-08-21
DK0726764T3 (da) 1999-12-20
ATE184785T1 (de) 1999-10-15
ES2136271T3 (es) 1999-11-16
KR100355247B1 (ko) 2003-01-24
NO961778D0 (no) 1996-05-02
CA2175057A1 (en) 1995-05-11
NO312809B1 (no) 2002-07-08
EP0726763B1 (en) 2000-03-29
NO961779L (no) 1996-05-02
NO312810B1 (no) 2002-07-08
DE69420859D1 (de) 1999-10-28
GR3032006T3 (en) 2000-03-31
PT726763E (pt) 2000-09-29
AU8132694A (en) 1995-05-23
DK0726763T3 (da) 2000-07-10
ATE191141T1 (de) 2000-04-15
CA2175896A1 (en) 1995-05-11
DE69423773D1 (de) 2000-05-04
EP0726763A1 (en) 1996-08-21
DE69420859T2 (de) 2000-01-05
NO961779D0 (no) 1996-05-02
JPH09511216A (ja) 1997-11-11
ES2144118T3 (es) 2000-06-01
NO961778L (no) 1996-06-25
EP0726764B1 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
GR3033817T3 (en) Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations
MY111791A (en) Aqueous gel retinoid dosage form.
ES2180635T3 (es) Metodo para reducir la grasa corporal en animales mediante la administracion de acido linoleico conjugado.
MX9704878A (es) Nuevos compuestos retinoides trienoicos y metodos de uso.
DE59805245D1 (de) Wässrige pflegende haut- und haarbehandlungsmittel
BR9912223A (pt) Agente terapêutico para crise hipercalcêmica
ES2161247T3 (es) Preparacion vaginal que contiene un peptido fisiologicamente activo.
DE60119976D1 (en) Thixotropes nasenspray
WO2002036090A3 (de) Kosmetische pflaster zur hautaufhellung
GR3030123T3 (en) Interdigitation-fusion liposomes containing arachidonic acid metabolites
ATE286739T1 (de) Verwendung einer pollenextrakt-haltigen verbindung zur behandlung erkrankungsbedingter gewichtszunahme
YU31104A (sh) Inhibicija virusa n-dokozanolom
DE69722178D1 (de) Therapeutischer wirkstoff für augenerkrankungen
NO20032035L (no) Terapeutiske midler for keratokonjuktivitis sykdommer omfattende farnesyleddiksyre som aktiv ingrediens
ECSP972162A (es) Formas solidas de dosificacion oral que contienen valsartan

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees